Who are MITT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Coenzyme Q10, hypoglycemic Agents(metformin), Metformin Small Pack, Q10 Coenzyme, Atovaquone / Proguanil, Atovaquone Proguanil and Artesunate Pyronaridine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mitt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MITT — Competitive Intelligence Brief

MITT (MITT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed Mitochondrial electron transport chain Small molecule Live · refreshed every 30 min

Target snapshot

MITT (MITT) — AstraZeneca. MITT is a mitochondrial-targeted therapeutic that enhances mitochondrial function and cellular energy production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MITT TARGET	MITT	AstraZeneca	marketed		Mitochondrial electron transport chain
Coenzyme Q10	Coenzyme Q10	Nanjing Medical University	marketed	Dietary supplement	Mitochondrial electron transport chain
hypoglycemic Agents(metformin)	hypoglycemic Agents(metformin)	First Affiliated Hospital of Wenzhou Medical University	marketed	Biguanide	AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain
Metformin Small Pack	Metformin Small Pack	GlaxoSmithKline	marketed	Biguanide	AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain
Q10 Coenzyme	Q10 Coenzyme	Central Hospital, Nancy, France	marketed	Mitochondrial cofactor / Antioxidant	Mitochondrial electron transport chain (Complexes I, II, III)
Atovaquone / Proguanil	Atovaquone / Proguanil	Radboud University Medical Center	marketed	Antimalarial combination	Mitochondrial electron transport chain (atovaquone); dihydrofolate reductase (proguanil)
Atovaquone Proguanil and Artesunate Pyronaridine	Atovaquone Proguanil and Artesunate Pyronaridine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium mitochondrial electron transport chain, dihydrofolate reductase, heme polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MITT — Competitive Intelligence Brief. https://druglandscape.com/ci/mitt. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab